Skyrizi Treatment Options: What Patients Should Know

Skyrizi (risankizumab-rzaa) is a prescription medication manufactured by AbbVie, a global biopharmaceutical company. This biological treatment is primarily used for moderate to severe plaque psoriasis and active psoriatic arthritis, offering relief to millions of patients worldwide seeking effective management options.

What Is Skyrizi and How Does It Work?

Skyrizi is an FDA-approved biologic medication that contains the active ingredient risankizumab-rzaa. As a monoclonal antibody, it works by targeting and inhibiting interleukin-23 (IL-23), a protein in your body that contributes to inflammation associated with psoriasis and psoriatic arthritis.

The medication works at the cellular level by blocking specific pathways in the immune system that lead to the overproduction of skin cells and joint inflammation. By targeting IL-23 specifically, Skyrizi helps reduce the symptoms of plaque psoriasis such as redness, thickness, and scaling of the skin, as well as joint pain and stiffness in psoriatic arthritis patients.

Treatment typically involves an injection administered under the skin. The standard dosing schedule begins with two starter doses, followed by maintenance doses every 12 weeks—a schedule many patients find more convenient than other biologics that require more frequent administration.

The Development and Manufacturing Process

Skyrizi undergoes a complex manufacturing process typical of biological medications. Unlike conventional drugs that are chemically synthesized, biologics like Skyrizi are created using living cells in highly controlled laboratory conditions.

The manufacturing process involves several critical steps: cell culture development, protein expression, purification, formulation, and quality testing. Each batch must meet strict quality standards before release, ensuring consistency, purity, and potency of the final product.

AbbVie maintains specialized manufacturing facilities equipped with advanced technology to produce Skyrizi. These facilities operate under Current Good Manufacturing Practice (cGMP) regulations enforced by regulatory authorities like the FDA, ensuring the highest standards of quality control throughout the production process.

Manufacturer Comparison: Skyrizi vs. Other Psoriasis Treatments

When comparing biological treatments for psoriasis and psoriatic arthritis, understanding the manufacturers behind them provides valuable context for patients and healthcare providers:

Medication	Manufacturer	Type	Administration
Skyrizi	AbbVie	IL-23 inhibitor	Every 12 weeks
Humira	AbbVie	TNF inhibitor	Every 2 weeks
Stelara	Janssen	IL-12/23 inhibitor	Every 8-12 weeks
Cosentyx	Novartis	IL-17 inhibitor	Monthly
Tremfya	Janssen	IL-23 inhibitor	Every 8 weeks

AbbVie, the manufacturer of Skyrizi, has established itself as a leader in immunology treatments. The company was formed in 2013 when it separated from Abbott Laboratories. Since then, AbbVie has built a strong portfolio of immunology medications, with Skyrizi becoming one of its flagship products after receiving FDA approval in 2019.

While Janssen (a division of Johnson & Johnson) and Novartis produce competing biologics, AbbVie's focus on longer dosing intervals with Skyrizi represents a potential advantage for patients seeking less frequent injections.

Benefits and Considerations of Skyrizi Treatment

Clinical trials have demonstrated Skyrizi's effectiveness, with many patients experiencing significant skin clearance. According to data published by Skyrizi, approximately 75% of patients achieved clear or almost clear skin after 16 weeks of treatment, and many maintained these results through continued treatment.

The less frequent dosing schedule of Skyrizi—once every 12 weeks after initial loading doses—offers convenience that may improve treatment adherence compared to medications requiring more frequent administration. This schedule means patients receive just four maintenance doses per year after the initial starter doses.

However, patients should consider several factors before starting treatment:

Immune system effects: As an immunosuppressant, Skyrizi may increase the risk of infections
Tuberculosis screening: Required before starting treatment
Allergic reactions: Though rare, can occur and require immediate medical attention
Pregnancy considerations: Limited data exists on use during pregnancy

Patients should discuss their complete medical history with healthcare providers to determine if Skyrizi is appropriate for their specific situation. The medication's safety profile continues to be monitored through post-marketing surveillance by AbbVie and regulatory authorities.

Access and Support Programs

The cost of biological treatments like Skyrizi can be substantial, often exceeding several thousand dollars per dose without insurance coverage. However, AbbVie offers several programs to improve access and affordability.

The Skyrizi Complete patient support program includes:

Insurance verification assistance
Savings cards for eligible commercially insured patients
Nurse Ambassador support for treatment guidance
Injection training resources
Patient assistance programs for those who qualify

Many patients with commercial insurance may pay as little as $5 per dose through the savings program, though eligibility requirements apply. Medicare and Medicaid patients have different options and should consult with healthcare providers about available assistance.

AbbVie also provides resources for healthcare professionals to help navigate insurance requirements, including prior authorization support and appeals assistance. These comprehensive support services reflect AbbVie's commitment to ensuring eligible patients can access their medications.

Conclusion

Skyrizi represents a significant advancement in the treatment of plaque psoriasis and psoriatic arthritis. As a product of AbbVie's research and manufacturing expertise, it offers patients an effective option with a convenient dosing schedule. When considering biological treatments, understanding not only the medication itself but also the manufacturer's reputation, support programs, and commitment to patient care provides valuable context for making informed healthcare decisions.

While Skyrizi has demonstrated impressive efficacy in clinical trials, patients should work closely with healthcare providers to determine if it's the right choice based on their specific medical history, insurance coverage, and treatment goals. With proper medical supervision and support from manufacturer programs, many patients may find that Skyrizi offers a manageable path toward clearer skin and improved joint function.

Citations

This content was written by AI and reviewed by a human for quality and compliance.